在血清Olfactomedin 4和阿尔茨海默氏病之间的Apolipoprotein E ε4-特定关系
Chunxiao Wei1,2, Guimei Zhang1,2, Xiaoshu Fu1,2
1Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Jilin University, Changchun, China.
Molecular neurobiology
|March 7, 2025
概括
在阿尔茨海默氏症患者中,血清OLFM4水平较高.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 免疫学 免疫学 免疫学
背景情况:
- Olfactomedin 4 (OLFM4) 涉及炎症,免疫调节,细胞亡和神经发育.
- OLFM4在阿尔茨海默病 (AD) 发病过程中的作用及其与阿波利波蛋白E (APOE) ε4状态的关联需要进行研究.
研究的目的:
- 检查血清OLFM4水平与阿尔茨海默病 (AD) 之间的相关性.
- 研究血清OLFM4,临床AD表型和阿波利波蛋白E (APOE) ε4状态之间的关系.
主要方法:
- 在122名AD患者和113名健康对照 (HC) 中量化了血清OLFM4水平.
- 分析了与认知功能和大脑体积的相关性.
- 多变量后勤回归评估了高OLFM4和APOE ε4.4的综合风险.
主要成果:
- 与HC相比,AD患者的血清OLFM4水平显著升高.
- 升高的OLFM4与认知能力下降和大脑缩相关.
- 高OLFM4和APOE ε4的组合显著增加了AD风险 (OR = 5.440).
结论:
- 血清OLFM4可能在AD病理学中发挥作用,并可以作为潜在的生物标志物.
- 在阿尔茨海默病中,OLFM4是潜在的治疗点.
- 在阿尔茨海默病中,APOE ε4可能会调解OLFM4的影响.
更多相关视频
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.7K
15:23Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease
Published on: May 13, 2010
19.3K
相关概念视频
01:26Alzheimer's Disease: Overview
412
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
412
01:22Alzheimer's Disease: Treatment
142
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
142